Cyclofenil treatment of scleroderma--a controlled study.

Area of Science:

• Rheumatology
• Dermatology
• Clinical Pharmacology

Background:

• Scleroderma is a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues.
• Current treatments for scleroderma have limited efficacy, necessitating the exploration of new therapeutic agents.

Purpose of the Study:

• To evaluate the efficacy and safety of cyclofenil in patients with scleroderma.
• To assess the impact of cyclofenil on subjective and objective measures of disease activity.

Main Methods:

• A double-blind, placebo-controlled, cross-over study was performed.
• Eleven patients with scleroderma participated, with each receiving cyclofenil and placebo for four-month treatment periods.
• Subjective and objective measurements were used to assess treatment response.

Main Results:

• No consistent or obvious response to cyclofenil was observed across subjective and objective measurements.
• One patient died due to scleroderma progression during active treatment.
• Four patients were withdrawn due to cyclofenil-attributed liver dysfunction.

Conclusions:

• Cyclofenil did not demonstrate significant clinical efficacy in this short-term study of scleroderma patients.
• The observed liver toxicity raises safety concerns regarding cyclofenil use.
• Further investigation into long-term effects and potential benefits is warranted but requires careful consideration of safety profile.